B

Bavarian Nordic A/S
CSE:BAVA

Watchlist Manager
Bavarian Nordic A/S
CSE:BAVA
Watchlist
Price: 198.4 DKK 3.09% Market Closed
Market Cap: 15.6B DKK
Have any thoughts about
Bavarian Nordic A/S?
Write Note

Bavarian Nordic A/S
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bavarian Nordic A/S
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
B
Bavarian Nordic A/S
CSE:BAVA
Operating Income
kr723.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
88%
Genmab A/S
CSE:GMAB
Operating Income
kr6B
CAGR 3-Years
25%
CAGR 5-Years
42%
CAGR 10-Years
48%
Zealand Pharma A/S
CSE:ZEAL
Operating Income
-kr1.1B
CAGR 3-Years
-2%
CAGR 5-Years
-16%
CAGR 10-Years
-36%
Ascendis Pharma A/S
NASDAQ:ASND
Operating Income
-€353.4m
CAGR 3-Years
5%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
F
Fluoguide AS
STO:FLUO
Operating Income
-kr43.9m
CAGR 3-Years
-26%
CAGR 5-Years
-285%
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Operating Income
-kr57.9m
CAGR 3-Years
3%
CAGR 5-Years
-2%
CAGR 10-Years
-11%
No Stocks Found

Bavarian Nordic A/S
Glance View

Market Cap
15.5B DKK
Industry
Biotechnology

Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The firm is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.

BAVA Intrinsic Value
168.42 DKK
Overvaluation 15%
Intrinsic Value
Price
B

See Also

What is Bavarian Nordic A/S's Operating Income?
Operating Income
723.6m DKK

Based on the financial report for Jun 30, 2024, Bavarian Nordic A/S's Operating Income amounts to 723.6m DKK.

What is Bavarian Nordic A/S's Operating Income growth rate?
Operating Income CAGR 10Y
88%

Over the last year, the Operating Income growth was -46%.

Back to Top